Table of Contents
PPT Slide
Safe Harbor
ArQule Profile
ArQule Product Portfolio
Extract from Wyeth R&D presentation June 2004
The ArQule Advantage
Oncology Opportunity
The Goal of Activated Checkpoint TherapySM (ACTSM ):
Mechanism of Action
PPT Slide
ACTSM - More Selective than Chemotherapy
ARQ 501 in combination with Taxol – Ovarian model
PPT Slide
ARQ 501: Safety Margin in animal models
ArQule’s Lead Anti-Cancer Compound ARQ 501
Clinical Development:ARQ 501 Phase 1 Trial
Centers of Excellence/Investigators
Phase 1 study update
Pharmacokinetics
Tumor response
Adverse events
Phase Ib/II plans
Research portfolio update
PPT Slide
Roche Partnership
ArQule Financials
Milestones 2004
ArQule Profile
|